Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2006-07-18
2006-07-18
Landsman, Robert S. (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
C530S300000
Reexamination Certificate
active
07078482
ABSTRACT:
The invention relates to NKAF II polypeptides, polynucleotides encoding the polypeptides, methods for producing the polypeptides, in particular by expressing the polynucleotides, and agonists and antagonists of the polypeptides. The invention further relates to methods for utilizing such polynucleotides, polypeptides, agonists and antagonists for applications, which relate, in part, to research, diagnostic and clinical arts.
REFERENCES:
patent: 5316933 (1994-05-01), Yoshimatsu et al.
patent: 5350836 (1994-09-01), Kopchick et al.
patent: 5476839 (1995-12-01), Scott et al.
patent: 6143867 (2000-11-01), Akerblom
patent: 0357067 (1990-03-01), None
patent: WO 97/37022 (1997-10-01), None
US 5,728,820, 03/1998, Akerblom (withdrawn)
Skolnick et al. Trends in Biotech. 18:34-39, 2000.
Bork P. Genome Research 10:398-400, 2000.
Doerks et al. Trends in Genetics 14:248-250, 1998.
Smith et al. Nature Biotechnology 15:1222-1223, 1997.
Brenner SE. Trends in Genetics 15:132-133, 1999.
Bork, et al. Trends in Genetics 12:425-427, 1996.
Cunningham BC et al. Science 244:1081-1085, 1989.
Li et al., “Human eosinophil major basic protein, a mediator of allergic inflammation, is expressed by alternative splicing from two promoters,”J. Biochem.,305:921-927 (1995).
Kita et al., “Eosinophil major basic protein induces degranulation and IL-8 production by human eosinophils,”J. Immunology4749-4758 (1995).
Barker et al., “Acidic polyamino acids inhibit human eosinophil granule major basic protein toxicity,”J. Clin. Invest.88:798-805 (1991).
Yoshimatsu et al., “Purification and cDNA cloning of a novel factor produced by a human T-cell hybridoma: sequence homology with animal lectins,”Molecular Immun.,29:537-546 (1992).
Kobayashi et al., “Natural killer (NK) cell activating factor produced by a human T-cell hybridoma,”Microbiol. Immunol.,35(11):981-993 (1991).
Yoshimatsu et al., “Serum levels of major basic protein in patients with or without eosinophilia: measurement by enzyme-linked immunosorbent assay,”Brit. J. of Haematology,86:490-495 (1994).
Plager et al., “A Novel and Highly Divergent Homolog of Human Eosinophil Granule Major Basic Protein,”J. Biol. Chem.,274(20):14464-14473 (1999).
Vukicevic et al. PNAS USA 93:9021-9026, 1996.
Massague J. Cell 49:437-8, 1987.
Pilbeam et al. Bone 14:717-720, 1993.
Skolnick et al., Trends in Biotech. 18:34-39, 2000.
Bork P. Genome Research 10:398-400, 2000.
Doerks et al. Trends in Genetics 14:248-250, 1998.
Smith et al. Nature Biotechnology 15:1222-1223, 1997.
Brenner SE. Trends in Genetics 15:132-133, 1999.
Bork et al. Trends in Genetics 12:425-427, 1996.
Gentz Reiner L.
Li Haodong
Ni Jian
Yu Guo-Liang
Human Genome Sciences Inc.
Human Genome Sciences Inc.
Landsman Robert S.
LandOfFree
Natural killer cell activating factor II does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Natural killer cell activating factor II, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Natural killer cell activating factor II will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3567625